e-learning
resources
Paris 2018
Monday, 17.09.2018
Granulomatous disorders: heterogeneous diseases with variable management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term outcomes of rituximab (RTX) therapy in recurrent Granulomatosis with Polyangiitis (GPA)
D. Gawryluk (Warsaw, Poland), J. Fijolek (Warsaw, Poland), E. Wiatr (Warsaw, Poland)
Source:
International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Session:
Granulomatous disorders: heterogeneous diseases with variable management
Session type:
Thematic Poster
Number:
3009
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Gawryluk (Warsaw, Poland), J. Fijolek (Warsaw, Poland), E. Wiatr (Warsaw, Poland). Long-term outcomes of rituximab (RTX) therapy in recurrent Granulomatosis with Polyangiitis (GPA). 3009
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effectiveness of rituximab (RTX) therapy in recurrent granulomatosis with polyangiitis (GPA)
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression
Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon
Year: 2018
Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Physiological characteristics in patients with microscopic polyangitis (MPA) and wegener‘s granulomatosis (WG)
Source: Eur Respir J 2004; 24: Suppl. 48, 327s
Year: 2004
Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab
Source: Eur Respir J 2006; 27: 644-646
Year: 2006
ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015
Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis
Source: Eur Respir J 2014; 43: 602-609
Year: 2013
Granulomatosis with polyangiitis (Wegener&s)
Source: Eur Respir Mon 2011; 54: 1-14
Year: 2011
Long-term treatment with infliximab in patients with sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 65s
Year: 2002
Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
Source: ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019
Year: 2020
Asthma follow-up and treatment in a group of 28 patients with eosinophilic granulomatosis with polyangiitis (EGPA)
Source: Annual Congress 2013 –Is it really asthma?
Year: 2013
Wegener's granulomatosis (WG) - clinical features and response to treatment in 18 cases
Source: Eur Respir J 2002; 20: Suppl. 38, 64s
Year: 2002
Granulomatous lung disease in lymphoma patient after rituximab treatment
Source: Virtual Congress 2020 – Interstitial lung diseases
Year: 2020
Clinical and radiological correlation of pulmonary complications in CHOP versus rituximab-CHOP regimen treated non-Hodgkin’s lymphoma in Thailand
Source: International Congress 2017 – Rare diseases
Year: 2017
Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM)
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019
Long-term follow-up in Churg-Strauss syndrome following IFN-α-induced remission
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Therapy with low dose methotrexate plus diprospan in patient with recalcitrant recidivating sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 541s
Year: 2006
Combined cytotoxic treatment (methotrexate and cyclophosphamide) in association with prednisone in sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 713s
Year: 2004
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept